Table 1.

Baseline characteristics comparing the 2 SARP cohorts, SARP III vs. SARP I&II, stratified by HSD3B1(1245) genotypes^*

	SARP III				SARP I& II
	AA	AC	CC	P value	AA	AC	CC	P value
N	146	131	41		80	79	25
Age, y	49.5 ± 14.5	48.7 ± 13.8	47.8 ± 14.2	0.762	43.3 ± 11.2	46.3 ± 13.6	42.7 ± 13.7	0.26
Female sex, n (%)	92 (63.0)	80 (61.1)	31 (75.6)	0.230	46 (57.5)	47 (59.5)	20 (80.0)	0.11
BMI†	30.2 ± 6.2	31.8 ± 8.6	33.4 ± 9.8	0.038	30.3 ± 7.2	30.5 ± 7.5	29.9 ± 6.9	0.93
Daily oral GC therapy, n (%)	23 (15.8)	24 (18.3)	8 (19.5)	0.787	35 (43.8)	30 (38.0)	10 (40.0)	0.76
Severe asthma, n (%)‡	82 (56.2)	77 (58.8)	20 (48.8)	0.530	80 (100)	79 (100)	25 (100)
FEV1/FVC ratio	0.84 ± 0.12	0.84 ± 0.12	0.90 ± 0.10	0.011	0.61 ± 0.13	0.64 ± 0.12	0.71 ± 0.11	0.026
Pre-FEV1, % of predicted value	71.8 ± 19.3	72.6 ± 21.8	77.9 ± 16.3	0.224	57.4 ± 19.2	61.1 ± 21.6	67.3 ± 23.7	0.09
Post-FEV1, % of predicted value	80.8 ± 20.2	80.3 ± 20.8	88.0 ± 16.5	0.083	73.5 ± 19.2	76.3 ± 20.7	79.3 ± 24.8	0.43

GC, daily oral glucocorticoid therapy; FVC, forced vital capacity; Post-, postbronchodilator; Pre-, prebronchodilator.

^*Plus–minus values are means ± SD.

^†The BMI is the weight in kilograms divided by the square of the height in meters.

^‡Analyzed SARP I&II cohort includes patients with severe asthma.